The Pulmonary Edema Therapeutic Market is primarily driven by the high prevalence and rising incidence of congestive heart failure worldwide. For instance, it is estimated that 26 million people worldwide suffer from congestive heart failure, and the incidence rate is sharply rising. The global market for pulmonary edoema therapies is anticipated to develop over the course of the forecast period as a result of a rise in the number of traffic accidents resulting in serious chest injuries, changing lifestyles, and rapidly growing toxic air pollution in industrialised nations. Additionally, it is projected that the introduction of new products and the substantial number of therapeutic medication candidates undergoing clinical trial studies will accelerate market expansion.
Read More:
https://knackersblogger.blogspot.com/2022/09/pulmonary-edema-therapeutics-market.html
